Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9205630 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL5465849 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL5467589 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL5458734 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL465471 | 1.00 | — | — | |
| SCHEMBL5471582 | 1.00 | TSHR (0.53) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL7697182 | 0.93 | TSHR (0.61) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL277225 | 0.93 | TSHR (0.61) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL95733 | 0.93 | TSHR (0.61) | TSHRTHRBMEN1KMT2ANAAA | |
| SCHEMBL4399689 | 0.93 | TSHR (0.61) | TSHRTHRBMEN1KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| EP-4399178-A1 | PROCESS FOR THE PRODUCTION OF HYDROGEN THROUGH ELECTRIFICATION OF WATER GAS SHIFT REACTION | TotalEnergies OneTech (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024137742-A1 | COMPOUNDS AND COMPOSITIONS AS FGFR3 DEGRADERS AND USES THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-12018267-B2 | Plants having increased tolerance to herbicides | BASF SE (DE) | 2024-06-25 | — | — | US | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| US-11992012-B2 | Diaminotriazine compounds | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| WO-2024103069-A1 | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | RIBOMETRIX, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024103067-A1 | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | RIBOMETRIX, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-0623598-A1 | APOPTOSIS REGULATOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0215435-B1 | 2-OXA-ISOCEPHEM COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-5153104-A | Negative-acting photothermographic imaging systems comprising also a nitrate, an initiator, a leuco dye and a binder; colorfastness; clean background | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-4831026-A | ANTIBIOTICS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
| US-4760064-A | Cardiotonic agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-07-26 | — | — | US | disclosed |
| EP-0148725-B1 | SULFONAMIDO-BENZAMIDE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1987-05-06 | — | — | EP | disclosed |
| EP-0215435-A1 | 2-Oxa-isocephem compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
| EP-0187322-A1 | Carbostyril compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-16 | — | — | EP | disclosed |
| US-4595780-A | Sulfonamido-benzamide derivatives | SHIONOGI & CO., LTD. (JP) | 1986-06-17 | — | — | US | disclosed |
| EP-0148725-A1 | Sulfonamido-benzamide derivatives | SHIONOGI & CO., LTD. (JP) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | KLK3, FOLH1, CA14 | TSHR 1586/4885THRB 1656/4885MEN1 81/4885 |
| US-11992012-B2 | Diaminotriazine compounds | DDT, DAZAP1, DDC | TSHR 3261/4885THRB 3578/4885MEN1 3474/4885 |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | TSHR 2174/4885THRB 580/4885MEN1 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.